Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants

Polskie Archiwum Medycyny Wewnetrznej

Volumn 126, Issue 9, 2016, Pages 688-696

  Weitz, Jeffrey I ^a,b   Jaffer, Iqbal H ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Bleeding risk; Direct oral anticoagulants; Periprocedural management; Venous thromboembolism

Indexed keywords

ANDEXANET ALFA; APIXABAN; CIRAPARANTAG; DABIGATRAN; EDOXABAN; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; COAGULATING AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

BODY WEIGHT; BRAIN HEMORRHAGE; BREAST FEEDING; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS, PHASE III AS TOPIC; COAGULANTS; DABIGATRAN; HUMANS; PATIENT SAFETY; PYRAZOLES; PYRIDINES; PYRIDONES; RIVAROXABAN; THIAZOLES; VENOUS THROMBOEMBOLISM;

EID: 84994226102     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3547     Document Type: Review

References (48)

1. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009; 28: 401-409.
2. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107: SI4-SI8.
3. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med. 1998; 158: 585-593.
4. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study. Arch Intern Med. 1999; 159: 445-453.
5. Kearon C. Natural history of venous thromboembolism. Circulation. 2003; 107: SI22-SI30.
6. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1 626 patients. Haematologica. 2007; 92: 199-205.
7. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125: 1-7.
8. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004; 350: 2257-2264.
9. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-2352.
10. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2013; 129: 764-772.
11. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-2510.
12. Buller HR, Prins MH, Lensing AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287-1297.
13. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799-808.
14. Buller HR, Decousus H, Grosso M, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406-1415.
15. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124: 1968-1975.
16. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.
17. Schulman S, Kearon C, Kakkar AK, et al. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. N Engl J Med. 2013; 368: 709-718.
18. Sindet-Pedersen C, Pallisgaard JL, Olesen JB, et al. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism-A systematic review and meta-analysis. Thromb Res. 2015; 136: 732-738.
19. Marik PE, Cavallazzi R. Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: A systematic review and meta-analysis. PLoS One. 2015; 10: e0143252.
20. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for longterm prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349: 631-639.
21. Weitz JI, Bauersachs R, Beyer-Westendorf J, et al. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost. 2015;114: 645-650.
22. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015; 33: 654-656.
23. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016; 149: 315-352.
24. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14: 1308-1313.
25. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11: 21.
26. Eikelboom JW, Weitz JI. Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol. 2012; 9: 260-262.
27. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014; 383: 955-962.
28. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015; 131: 157-164.
29. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013; 368: 2113-2124.
30. Boehringer-Ingelheim. Product Monograph: Pradaxa 2016. Available from: http://www.boehringeringelheim.ca/content/dam/internet/opu/ca-EN/documents/humanhealth/product-monograph/PradaxaPMEN.pdf. Accessed August 31, 2016.
31. Bayer. Product Monograph: Xarelto 2016. Available from: http://www. bayer.ca/omr/online/xarelto-pm-en.pdf. Accessed August 31, 2016.
32. Pfizer. Product Monograph: Eliquis 2016. Available from: http://www.pfizer.ca/sites/g/files/g10028126/f/201607/ELIQUIS-PM-184464-16June2016-E-marketed.pdf. Accessed August 31, 2016.
33. Daiichi-Sankyo. Prescribing Information: Savaysa 2016. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/206316lbl.pdf. Accessed August 31, 2016.
34. Benzon HT, Avram MJ, Green D, et al. New oral anticoagulants and regional anaesthesia. Br J Anaesth. 2013; 111: SI96-SI113.
35. Weitz JI, Pollack CV Jr. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015; 114: 1113-1126.
36. Pollack CV Jr. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J. 2016; 33: 423-340.
37. Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14: 623-627.
38. Eikelboom JW, Quinlan DJ, van Ryn J, et al. Idarucizumab: The antidote for reversal of dabigatran. Circulation. 2015; 132: 2412-2422.
39. Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373: 511-520.
40. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19: 446-351.
41. Yeh CH, Fredenburgh JC, Weitz JI. The real decoy: an antidote for factor Xa-directed anticoagulants. Circ Res. 2013; 113: 954-957.
42. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015; 373: 2413-2424.
43. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016. [Epub ahead of print].
44. Sullivan DW Jr, Gad SC, Laulicht B, et al. Nonclinical safety assessment of PER977: A small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol. 2015; 34: 308-317.
45. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371: 2141-2142.
46. Ansell JE, Laulicht BE, Bakhru SH, et al. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res. 2016.
47. Baumann Kreuziger LM, Keenan JC, Morton CT, et al. Management of the bleeding patient receiving new oral anticoagulants: A role for prothrombin complex concentrates. Biomed Res Int. 2014; 2014: 583794.
48. Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015; 131: 82-90.